News and Publications

2018 Multidisciplinary Head and Neck Cancers Symposium Press Kit

WATCH – News Briefing: Highlights from the 2018 Multidisciplinary Head and Neck Cancers Symposium

News Briefing
Press Registration
Press Office Hours and Contacts
Embargo Policy and Access to Abstracts
News Planning Team

The 2018 Multidisciplinary Head and Neck Cancers Symposium is a two-and-a-half-day meeting for the entire head and neck cancer community that provides the most up-to-date information on multidisciplinary therapies, the latest clinical research, new treatment strategies, supportive care, scientific breakthroughs and toxicity mitigation. The meeting is cosponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO) and the American Head & Neck Society (AHNS).

Interactive and case-based educational sessions will cover new multidisciplinary therapies, immunotherapy, treatment guidelines, new staging systems and supportive care in head and neck cancer. Oral abstract and poster sessions will highlight cutting-edge science and evidence-based practice, focused on topics such as oral cavity, tonsil, base of tongue, laryngeal, thyroid, salivary gland and skin cancers of the head and neck, as well as recurrent metastatic disease, locally advanced disease and survivorship.

For more information, visit the symposium website and schedule of events.

News Briefing

Download the full slide presentation from the news briefing.

WATCH – News Briefing: Highlights from the 2018 Multidisciplinary Head and Neck Cancers Symposium

Researchers presented findings from four top-rated studies in an online presscast on Tuesday, February 13, 2018, from 12:00 p.m. to 1:30 p.m. Eastern time:

  • A randomized, open-label, multicenter, global phase 2 study of durvalumab (D), tremelimumab (T), or D Plus T in patients with PD-L1 low/negative recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CONDOR (Abstract 1), presented by Dr. Lillian Siu of the Princess Margaret Cancer Centre (news release, briefing slides)
  • Safety evaluation of nivolumab (Nivo) concomitant with platinum-based chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504 (Abstract 2), presented by Dr. Maura Gillison of the University of Texas MD Anderson Cancer Center (news release, briefing slides)
  • OPTIMA—A phase II trial of induction chemotherapy response-stratified RT dose and volume de-escalation for HPV+ oropharynx cancer: Efficacy, toxicity, and HPV subtype analysis (Abstract 5), presented by Dr. Tanguy Seiwert of the University of Chicago (news release, briefing slides)
  • A phase II trial of cabozantinib for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting (Abstract 8), presented by Dr. Marcia Brose of the University of Pennsylvania School of Medicine (news release, briefing slides)

Press Registration

Complimentary registration is available for professional journalists representing media organizations for the express purpose of gathering news and information to produce press coverage of the symposium. Press registration is open to representatives of print, broadcast and online media outlets, including health care trade media (collectively known as press), as well as public information officers from educational institutions, government agencies and nonprofit cancer research organizations presenting research at the symposium. Reporters registered by February 9, 2018, will receive an embargoed press kit.

Applicants may be asked to provide media credentials, a letter of assignment and/or bylined articles. Exhibitors are not permitted to register as press unless they can provide proof of editorial assignment from an accredited news organization that meets the above criteria. Public relations, marketing and/or advertising representatives, financial analysts, book publishers and book authors, and individuals from communications, print or online promotion services are welcome to register as regular attendees, however, they are not permitted to register as press. ASTRO reserves the right to bar from this and future meetings any journalist who misuses press privileges to engage in activities other than journalistic pursuits.

Press Office and Contacts

There will be a press office in the Westin Kierland Resort and Spa open Thursday, February 15 and Friday, February 16 during local business hours. Rooms also are available to reserve for media interviews.

Questions about the press program, press office, press registration and expert availability may be directed to ASTRO’s media relations team at 703-286-1600.

Embargo Policy and Access to Abstracts

All abstracts to be presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium are embargoed until 8:00 a.m. Mountain time, Thursday, February 15, 2018, or until they are presented at an ASTRO news briefing, whichever occurs first. The embargo policy applies to all abstracts regardless of whether information is obtained from another source. Failure to abide by this embargo policy may result in suspension of press credentials. Questions about the embargo policy may be directed to ASTRO’s media relations team.

The full text of the abstracts selected for oral and poster presentation will be available online at the start of the symposium. Abstracts also will be published in a supplement of the International Journal of Radiation Oncology • Biology • Physics (www.redjournal.org).

News Planning Team

Jimmy Caudell, MD, PhD, Moffitt Cancer Center
Robert L. Ferris, MD, PhD, FACS, UPMC Hillman Cancer Center
Robert I. Haddad, MD, Brigham and Women's Hospital
Danielle Margalit, MD, MPH, Dana-Farber Cancer Institute
Maie St. John, MD, PhD, FACS, David Geffen School of Medicine, UCLA
Cherie-Ann O. Nathan, MD, Louisiana State University Health Sciences Center
Francis P. Worden, MD, University of Michigan Comprehensive Cancer Center